Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Leilani, Matsuoka, Osamu, Inoue, Satoshi, Inoue, Takahiro, Meng, Ya, Nakama, Takahiro, Kato, Kumiko, Pandey, Aseem, Chang, Lee-Jah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227668/
https://www.ncbi.nlm.nih.gov/pubmed/31634025
http://dx.doi.org/10.1080/21645515.2019.1677437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227668/
https://www.ncbi.nlm.nih.gov/pubmed/31634025
http://dx.doi.org/10.1080/21645515.2019.1677437

Ejemplares similares